Navigation Links
Australian Biotech Ceridia Pty Ltd Completes Successful Human Clinical Trial
Date:7/26/2011

ADELAIDE, Australia, July 26, 2011 /PRNewswire/ -- Ceridia Pty Ltd., a biotechnology company focused on reformulating and developing therapeutic drugs, announce the successful completion of Phase 1 Proof-of-Concept study of its novel LipoCeramic ibuprofen formulation, CER006.  CER006 was designed to be a model formulation to establish safety and tolerability of Ceridia's LipoCeramic reformulation technology but also to attain pharmacokinetic information in humans.

Trial demonstrates that the technology is safe and well tolerated. Study also suggests fast and improved delivery of ibuprofen when comparing with branded market leader.

Based on the safety and pharmacokinetics data from this 4-arm blinded study, Ceridia plans to commence a number of bio-equivalence and bioavailability trials which will include anti-inflammatory, anti-infective and oncology drugs.

"We are very pleased to demonstrate that Ceridia's LipoCeramic platform technology is safe and well tolerated in humans.  It is a clinical validation of more than 10 years of research and development," said Dr Gregor Rozenberg, Ph.D., CEO, Ceridia. "We are now poised to initiate a number of Phase 2 studies with the aim of reformulating and improving the clinical profiles of several therapeutic drugs.  Commercialisation can now be accelerated."

Ceridia Pty Ltd is supported by ITEK, the intellectual property commercialisation arm of UniSA and has entered into collaborations with Pharma and Biotech using its innovative reformulation technology to improve existing and novel drugs. The company is seeking additional investment and partnerships.

Reformulating approved drugs enables reprofiling or repurposing of therapeutic agents. This in turn provides new commercial opportunities in an abbreviated regulatory environment. This reduces development times significantly and produces better drugs quicker and cheaper.

Ceridia

Ceridia is a privately owned spin-out company of the University of South Australia.  Ceridia is commercializing a novel method of reformulating oil-soluble compounds.  A silica-lipid nano-encapsulation platform technology has been developed and protected by patents worldwide.  This technology enables the pharmaceutical and biotechnology industry to improve efficacy, bio-availability and stability of drugs and help reduce their time to market.  The technology is clinically proven to be completely safe, uses no synthetic, toxic or corrosive solvents. The manufacturing process is straightforward and can be quickly transferred into most API manufacturing sites and requires no additional capital expenditure.  Human clinical trials indicate improved clinical profile and quicker drug uptake.

Contact:
Gregor Rozenberg, CEO
Email: gregor@ceridia.com.au
Website: www.ceridia.com.au


'/>"/>
SOURCE Ceridia Pty Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Australian Center Readies Brain Research Program for Addition of Elekta MEG System
2. Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, ChemGenex Pharmaceuticals Limited
3. OrthoAccel Technologies, Inc. and AB Orthodontics Announce Partnership and Australian Product Introduction
4. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
5. New Australian Technology: Detecting Breast Cancer With Hair
6. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
7. Top 5 Ways to Get Insider Track on Healthcare, Pharma & Biotech Discoveries & Latest News
8. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
9. 2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent
10. Lilly Announces New Investment to Further Boost Its Biotechnology Capabilities
11. Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)...  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... treat life-threatening diseases, today announced results for the ... 2015. --> --> ... our last quarterly call, we strategically advanced pre-clinical ... to establish the Aethlon Hemopurifier® as a leading ...
(Date:2/4/2016)... , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) today announced ... Pfizer Inc. and President of Pfizer Global Supply, has been ... February 4, 2016. In addition, the Company announced that Mr. ... audit committee since 2010, has retired from the AMRI Board ... to his other business ventures.  William S. ...
(Date:2/4/2016)... -- --> --> ... Automated External Defibrillator (AED) Market by Product (Semi-Automated External ... Hospitals, Homecare & Nursing Homes) - Forecast to 2019", ... and segments the concerned market with an analysis and ... grow to about $367.0 million by 2019, at a ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... ... stage for new clinical and scientific initiatives have all marked the last 12 ... appointed President and CEO of the nation’s oldest cancer center, Candace S. Johnson, ...
(Date:2/5/2016)... Rosa, CA (PRWEB) , ... February 05, 2016 ... ... pleased to announce the addition of micro-needling services in their Napa Valley office. ... The founders of Plastic Surgery Associates, Dr. Canales and Dr. Furnas, are part ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
(Date:2/5/2016)... ... , ... Give To Cure today announced that it is working ... To Cure’s campaign that is crowdfunding clinical trials to help find cures faster for ... a smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. ...
Breaking Medicine News(10 mins):